aibioGRML Greenland Mines Ltd
Greenland Mines (GRML) news
Greenland Mines Ltd is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GRML, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Greenland Mines news
We have not published a story on Greenland Mines yet. When there is news, it will appear here.
What Greenland Mines does
Greenland Mines Ltd, formerly known as Klotho Neurosciences, Inc., develops essential medicines for cancer, cardiovascular and neurodegenerative disorders. Its common stock and warrants trade on Nasdaq as GRML and GRMLW. The company holds two licensed platforms. The first is a generic drug portfolio built on five market-approved anti-cancer drugs approved for sale in Germany, acquired on September 12, 2022, together with a biosimilar biologics platform of two off-patent bio generic antibodies licensed from Reliance Life Sciences. The second is a gene therapy platform that uses a therapeutic protein called Klotho to address age-associated neurologic diseases, with exclusive worldwide rights to the alpha-Klotho sequence licensed from the Autonomous University of Barcelona. That program is pre-clinical. In March 2026 the company completed the acquisition of Greenland Mines Corp, a transaction that expands its operations into the development and mining of critical and precious minerals.
| Product or program | What it is | Stage |
|---|---|---|
| Generic anti-cancer drug portfolio | Five market-approved anti-cancer drugs, including FOLFOX and FOLFIRI components | market-approved in Germany |
| Biosimilar biologics platform | Off-patent biologic antibodies licensed from Reliance Life Sciences | clinical-stage |
| Klotho gene therapy | Gene therapy to produce Klotho protein for neurodegenerative diseases | pre-clinical |
Greenland Mines annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $634,187 | $0 |
| Net income (loss) | -$10.6 million | -$6.2 million |
| Cash from operations | -$5.9 million | -$2.9 million |
| Cash and equivalents | $7.2 million | $63,741 |
Questions about Greenland Mines
What is the ticker symbol of Greenland Mines?
Greenland Mines Ltd trades under the ticker GRML on NASDAQ.
Where is Greenland Mines listed?
Greenland Mines Ltd is listed on NASDAQ.
Which country or territory is Greenland Mines listed under?
Our directory records Greenland Mines Ltd under United States.
Does aibio.space cover Greenland Mines?
aibio.space lists Greenland Mines Ltd among 2,820 public biotech companies and publishes its news here as stories appear.
What does Greenland Mines develop?
Greenland Mines Ltd, formerly known as Klotho Neurosciences, Inc., develops essential medicines for cancer, cardiovascular and neurodegenerative disorders. Its common stock and warrants trade on Nasdaq as GRML and GRMLW.
What is Generic anti-cancer drug portfolio from Greenland Mines?
Generic anti-cancer drug portfolio: Five market-approved anti-cancer drugs, including FOLFOX and FOLFIRI components Stage: market-approved in Germany.
What is Biosimilar biologics platform from Greenland Mines?
Biosimilar biologics platform: Off-patent biologic antibodies licensed from Reliance Life Sciences Stage: clinical-stage.
Is Greenland Mines profitable?
Greenland Mines Ltd reported a net loss of $10.6 million for the fiscal year ended Dec 31, 2025, and used $5.9 million of cash in operations, per its annual report to the SEC.
How much does Greenland Mines spend on research and development?
$634,187 in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Greenland Mines have?
$9.3 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: Greenland Mines
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Stock chart
Listing details
- Company
- Greenland Mines Ltd
- Ticker
- GRML
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction